Medicine Advances (Dec 2023)

Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

  • Yi‐Long Wu,
  • Shun Lu,
  • Ying Cheng,
  • Qing Zhou,
  • Hai‐Yan Tu,
  • Qing‐Hua Zhou,
  • Lv‐Hua Wang,
  • Li Zhang,
  • Jian‐Ying Zhou,
  • Cheng Huang,
  • Ming Chen,
  • Cheng‐Ping Hu,
  • Shao‐Kun Chuai,
  • Xiao‐Nan Wang,
  • Xiao‐Qing Liu,
  • Ji‐Wei Liu,
  • Peng‐Hui Zhou,
  • Wei‐Zhi Chen,
  • Ling‐Hua Yan,
  • Yun‐Peng Liu,
  • An‐Wen Liu,
  • Xu‐Chao Zhang,
  • Hui Li,
  • Rong‐Rong Chen,
  • Dong‐Mei Lin,
  • Cong‐Ying Xie,
  • Zheng‐Fei Zhu,
  • Hui‐Ying Liang,
  • Yong Song,
  • Xiao‐Rong Dong,
  • Ming‐Fang Zhao,
  • Gui‐Bin Qiao,
  • Jiu‐Wei Cui,
  • Zi‐Ming Li,
  • Zhi‐Jie Wang,
  • Xiao‐Yuan Chen,
  • Nong Yang,
  • Gen Lin,
  • Pan‐Wen Tian,
  • Yun Fan,
  • Qi‐Bin Song,
  • Yuan Chen,
  • Jian‐Chun Duan,
  • Jia‐Lei Wang,
  • Bo Zhu,
  • Bu‐Hai Wang,
  • Jun Zhao,
  • Qi‐Tao Yu,
  • Li‐Feng Wang,
  • Hai‐Bo Zhang,
  • Jie Hu,
  • Rui Ma,
  • Tong‐Mei Zhang,
  • Jie Lin,
  • Qian Chu,
  • Sheng‐Xiang Ren,
  • Yu Yao,
  • Lin Wu,
  • Hui‐Juan Wang,
  • Fang Wu,
  • Wen‐Zhao Zhong,
  • Yi Hu,
  • Ke‐Neng Chen,
  • Jian Zhao,
  • Li Zhang,
  • Fan Yang,
  • Qun Wang,
  • Dong‐Sheng Yue,
  • Jian‐Ya Zhou,
  • Peng Shen,
  • Jia‐Tao Zhang,
  • Xiao‐Long Yan,
  • Mei‐Juan Huang,
  • Wei‐Neng Feng,
  • Li Li,
  • Chinese Association of Lung Cancer, Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG)

DOI
https://doi.org/10.1002/med4.44
Journal volume & issue
Vol. 1, no. 4
pp. 293 – 305

Abstract

Read online

Abstract The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challenge for diagnosis and therapeutic targeting. In the never‐smokers/low smokers category with mutations such as EGFR and HER2, the efficacy of immune checkpoint inhibitors (ICIs) remains suboptimal, attributed to lower PD‐L1 expression and tumor mutation burden (TMB). However, heavy smokers, often with mutations like KRAS, may derive benefits from ICIs, as supported by trials like CheckMate‐057. With the complex landscape of these drivers and their clinical implications, the summit culminated in six pivotal consensus points, aiming to guide future research and clinical decisions. Despite the advancements, the detection, interpretation, and therapeutic strategies involving these drivers necessitate further exploration and standardization.

Keywords